Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"

Summary

This is an international prospective, multicentre, unblinded, randomised-controlled trial. The primary aim is to assess a targeted screening strategy to detect undiagnosed heart failure in high-risk patients.

Conditions

• Heart Failure
• Cardiovascular Diseases

Interventions

DIAGNOSTIC_TEST

NT-proBNP

Patients will undergo an NT-proBNP which will guide their future involvement within the study. Patients with an NT-proBNP of ≥125 pg/mL will undergo transthoracic echocardiogram along with a clinical assessment - any diagnosis of HF will result in patients undergoing referral for initiation of guideline directed medical therapy (for HF).

Sponsors & Collaborators

• University of Glasgow

  collaborator OTHER

• National Heart Centre Singapore

  collaborator OTHER

• Karolinska University Hospital

  collaborator OTHER

• Uppsala University

  collaborator OTHER

• Montreal Heart Institute

  collaborator OTHER

• Rigshospitalet, Denmark

  collaborator OTHER

• University of British Columbia

  collaborator OTHER

• The Cleveland Clinic

  collaborator OTHER

• Université de Montréal

  collaborator OTHER

• AstraZeneca

  collaborator INDUSTRY

• Roche Pharma AG

  collaborator INDUSTRY

• Us2.ai

  collaborator UNKNOWN

• NHS Greater Glasgow and Clyde

  lead OTHER

Principal Investigators

• Mark C Petrie, MbChB · University of Glasgow

• Carolyn SP Lam · Duke-NUS Graduate Medical School

Study Design

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

40 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-12-22

Primary Completion

2024-06-21

Completion

2032-12-21

FDA Device

Yes

Countries

• United States
• Canada
• Denmark
• Sweden
• United Kingdom

Study Locations